ADMINUSER, Author at Ose Immunotherapeutics - Société de biotechnologie intégrée qui développe des immunothérapies innovantes - Page 2 of 2
ADMINUSER, Author at Ose Immunotherapeutics - Société de biotechnologie intégrée qui développe des immunothérapies innovantes - Page 2 of 2
  • Our Company
    • Presentation
    • Management Team
    • Board of directors
    • Scientific Advisory Board
    • Contact
  • Products
    • Tedopi®
    • OSE-279
    • OSE-127/Lusvertikimab
    • FR104/VEL-101
    • BI 770371
    • ABBV-230
    • CLEC-1
  • Research & Development
    • Scientific publications
  • Investors
    • Press Releases
    • Regulated information
    • Financial documents
    • General Shareholders’ meetings
  • Partnerships
    • Pharma partnerships
    • Clinical partnerships
    • Academic and public Partnerships
  • News
    • Agenda
    • Press Releases
  • Contact
en
  • fr

Author: ADMINUSER

January 2019

Article 10
January 2019

Article 11
January 2019

Article 12
January 2019

Article 13
January 2019

Article 14
January 2019

Article 15
  • Précédent
  • 1
  • 2

Head Office

22, boulevard Benoni Goulin
44200 Nantes – France

Tel : +33 (0)2 28 29 10 10

Email : contact@ose-immuno.com

Paris Office

10, place de Catalogne
75014 Paris – France

Tel : +33 (0)1 43 29 78 57

Fax : +33 (0)1 42 03 04 16

Our Company
Products
Investors
Agenda
Research & Development
Partnerships
Press Releases
Follow us
©2021 ose-immuno
Financial documents
Legal information and Personal data protection policy
Site internet créé par Adveris